SAB Biotherapeutics
SABS----
SAB Biotherapeutics (SABS)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address im...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
SAB Biotherapeutics Analyst Rating
View MoreForecast & Rating
Jun 24, 2026Price forecast
$11.18212.34%
Forecast & RatingStrong buy
11analysts
- Strong buy90.91%
- Buy9.09%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 16 at 01:00 AM
SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% - Still a Buy?
- PUBT · Jul 7 at 07:06 AM
Breakthrough T1D awards grant to support UF-led PRISE-hATG study of SAB Bio’s SAB-142 in stage 3 type 1 diabetes
- PUBT · Jun 18 at 03:36 PM
SAB Biotherapeutics shareholders elect four Class II directors at annual meeting
- Tip Ranks · Jun 16 at 08:15 AM
Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)
- benzinga_article · Jun 15 at 12:05 PM
12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga_article · Jun 15 at 08:55 AM
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday
